ArticleInternational journal of clinical pharmacy2026

Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system.

Yuwen Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.